MedTrace Logo

The Influence of Race and MitoQ Supplementation on Skin Blood Flow in the Cold

NCT06784531 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-30

No results posted yet for this study

Summary

Individuals who operate in cold weather are at risk of developing cold injuries, for example, frostbite. They also often experience a loss of hand function and joint mobility due to a decrease in skin temperature and blood flow.

In addition, the risk of getting a cold injury is higher in the Black population compared to other racial and ethnic groups. Increases in oxidant compounds can cause the blood vessels in the skin to narrow and decrease skin temperature in the cold. However, it is unknown whether the higher risk of cold injury in Black individuals is because of a greater amount of oxidant compounds in the blood vessels. The purpose of this research is to see if an antioxidant supplement called MitoQ can help to improve skin temperature and blood flow in the cold and if the improvement is greater in Black individuals.

Conditions

  • Cold Exposure

Interventions

DIETARY_SUPPLEMENT

Mitoquinone mesylate (MitoQ)

Four 20 mg MitoQ capsules (80 mg total) are ingested orally.

DIETARY_SUPPLEMENT

Placebo

Four placebo (microcrystalline cellulose) capsules are ingested orally.

OTHER

Cold Water Hand Immersion

Volunteers place one hand in cold (54°F) water for 30 minutes.

OTHER

Cold Air Exposure

Volunteers sit in cold (41°F) air for 90 minutes.

Sponsors & Collaborators

  • United States Army Research Institute of Environmental Medicine

    lead FED

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2025-10-28
Completion
2025-10-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06784531 on ClinicalTrials.gov